Oric Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (ORIC)
CUSIP: 68622P109
Q2 2025 13F Holders as of 30 Jun 2025
- Type / Class
- Equity / Common Stock, par value $0.0001 per share
- Shares outstanding
- 97,866,034
- Total 13F shares
- 93,349,298
- Share change
- +14,060,740
- Total reported value
- $947,499,065
- Put/Call ratio
- 0.98%
- Price per share
- $10.15
- Number of holders
- 140
- Value change
- +$169,716,912
- Number of buys
- 75
- Number of sells
- 85
Quarterly Holders Quick Answers
What is CUSIP 68622P109?
CUSIP 68622P109 identifies ORIC - Oric Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 68622P109:
Top shareholders of ORIC - Oric Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| VIKING GLOBAL INVESTORS LP |
13D/G
13F
|
Company |
10%
|
8,729,345
|
$95,149,860 | +$23,507,430 | 30 Jun 2025 | |
| Nextech Crossover I GP S.a r.l. |
13D/G
|
— |
8.4%
|
7,162,637
|
$78,072,743 | $0 | 30 Jun 2025 | |
| PFIZER INC |
3/4/5
13F
|
10%+ Owner · Company |
5.5%
from 13F
|
5,376,344
|
$46,160,752 | — | 23 Dec 2022 | |
| COLUMN GROUP II, LP |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
3,568,255
|
$30,636,680 | — | 12 Nov 2021 | |
| BlackRock, Inc. |
13F
|
Company |
5.6%
|
5,435,087
|
$30,327,787 | — | 31 Mar 2025 | |
| Nextech Invest, Ltd. |
13F
|
Company |
5.4%
|
5,285,714
|
$29,494,284 | — | 31 Mar 2025 | |
| Point72 Asset Management, L.P. |
13D/G
|
— |
5.1%
|
4,401,659
|
$23,372,809 | $0 | 29 May 2025 | |
| ALKEON CAPITAL MANAGEMENT LLC |
13F
|
Company |
4.1%
|
4,004,096
|
$22,342,856 | — | 31 Mar 2025 | |
| Column Group LLC |
13F
|
Company |
3.6%
|
3,540,777
|
$19,757,536 | — | 31 Mar 2025 | |
| EcoR1 Capital, LLC |
13F
|
Company |
3.5%
|
3,418,068
|
$19,072,819 | — | 31 Mar 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
3.3%
|
3,215,887
|
$17,944,648 | — | 31 Mar 2025 | |
| VR Adviser, LLC |
13F
|
Company |
3.3%
|
3,182,527
|
$17,758,501 | — | 31 Mar 2025 | |
| FMR LLC |
13D/G
13F
|
Company |
3.5%
|
2,467,809
|
$13,967,797 | $0 | 31 Dec 2024 | |
| STATE STREET CORP |
13F
|
Company |
2.2%
|
2,196,549
|
$12,256,743 | — | 31 Mar 2025 | |
| NEA Management Company, LLC |
13F
|
Company |
2.2%
|
2,195,545
|
$12,251,141 | — | 31 Mar 2025 | |
| Vivo Capital, LLC |
13F
|
Company |
2.1%
|
2,080,450
|
$11,608,911 | — | 31 Mar 2025 | |
| SILVERARC CAPITAL MANAGEMENT, LLC |
13F
|
Company |
2.1%
|
2,060,240
|
$11,496,139 | — | 31 Mar 2025 | |
| First Turn Management, LLC |
13F
|
Company |
2.1%
|
2,027,430
|
$11,313,059 | — | 31 Mar 2025 | |
| BALYASNY ASSET MANAGEMENT L.P. |
13F
|
Company |
2.1%
|
2,007,272
|
$11,200,578 | — | 31 Mar 2025 | |
| Commodore Capital LP |
13F
|
Company |
2%
|
2,000,000
|
$11,160,000 | — | 31 Mar 2025 | |
| Boxer Capital Management, LLC |
13F
|
Company |
1.8%
|
1,732,571
|
$9,667,746 | — | 31 Mar 2025 | |
| Frazier Life Sciences Public Fund, L.P. |
13D/G
|
James N. Topper |
2%
|
1,410,193
|
$7,981,692 | $0 | 31 Mar 2025 | |
| Frazier Life Sciences Management, L.P. |
13F
|
Company |
1.4%
|
1,410,193
|
$7,868,877 | — | 31 Mar 2025 | |
| MPM BioImpact LLC |
13F
|
Company |
1.4%
|
1,399,514
|
$7,809,288 | — | 31 Mar 2025 | |
| ArrowMark Colorado Holdings LLC |
13F
|
Company |
1.4%
|
1,346,189
|
$7,511,735 | — | 31 Mar 2025 | |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
|
Company |
1.4%
|
1,332,860
|
$7,438,000 | — | 31 Mar 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.3%
|
1,305,991
|
$7,288,937 | — | 31 Mar 2025 | |
| FRANKLIN RESOURCES INC |
13F
|
Company |
1%
|
1,022,790
|
$5,707,168 | — | 31 Mar 2025 | |
| Siren, L.L.C. |
13F
|
Individual |
1%
|
1,007,575
|
$5,622,269 | — | 31 Mar 2025 | |
| Euclidean Capital LLC |
13F
|
Company |
1%
|
989,410
|
$5,520,908 | — | 31 Mar 2025 | |
| SUPERSTRING CAPITAL MANAGEMENT LP |
13F
|
Company |
0.84%
|
819,194
|
$4,571,103 | — | 31 Mar 2025 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
0.74%
|
727,830
|
$4,063,926 | — | 31 Mar 2025 | |
| ORBIMED ADVISORS LLC |
13F
|
Company |
0.72%
|
700,000
|
$3,906,000 | — | 31 Mar 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.56%
|
546,746
|
$3,050,844 | — | 31 Mar 2025 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
0.52%
|
511,889
|
$2,856,341 | — | 31 Mar 2025 | |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC |
13F
|
Company |
0.52%
|
509,179
|
$2,841,219 | — | 31 Mar 2025 | |
| Schonfeld Strategic Advisors LLC |
13F
|
Company |
0.44%
|
426,902
|
$2,382,111 | — | 31 Mar 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.42%
|
408,505
|
$2,279,458 | — | 31 Mar 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.3%
|
294,784
|
$1,644,895 | — | 31 Mar 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.27%
|
259,801
|
$1,449,689 | — | 31 Mar 2025 | |
| SUVRETTA CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.26%
|
255,000
|
$1,422,900 | — | 31 Mar 2025 | |
| DAFNA Capital Management LLC |
13F
|
Company |
0.25%
|
242,000
|
$1,350,360 | — | 31 Mar 2025 | |
| SPHERA FUNDS MANAGEMENT LTD. |
13F
|
Company |
0.24%
|
234,834
|
$1,310,374 | — | 31 Mar 2025 | |
| Atom Investors LP |
13F
|
Company |
0.22%
|
210,706
|
$1,175,739 | — | 31 Mar 2025 | |
| Parkman Healthcare Partners LLC |
13F
|
Company |
0.21%
|
203,006
|
$1,132,773 | — | 31 Mar 2025 | |
| CANTOR FITZGERALD, L. P. |
13F
|
Individual |
0.2%
|
200,000
|
$1,116,000 | — | 31 Mar 2025 | |
| FRED ALGER MANAGEMENT, LLC |
13F
|
Company |
0.18%
|
178,722
|
$997,269 | — | 31 Mar 2025 | |
| WELLINGTON MANAGEMENT GROUP LLP |
13F
|
Company |
0.18%
|
178,217
|
$994,451 | — | 31 Mar 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0.17%
|
168,671
|
$941,184 | — | 31 Mar 2025 | |
| Nuveen, LLC |
13F
|
Company |
0.17%
|
167,502
|
$934,661 | — | 31 Mar 2025 |
Institutional Holders of Oric Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (ORIC) as of Q2 2025
As of 30 Jun 2025,
Oric Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (ORIC) was held by
140 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
93,349,298 shares.
The largest 10 holders included
Nextech Invest, Ltd., VR ADVISER, LLC, VIKING GLOBAL INVESTORS LP, Pfizer Inc, SR One Capital Management, LP, ALKEON CAPITAL MANAGEMENT LLC, NEA Management Company, LLC, BlackRock, Inc., Column Group LLC, and Vivo Capital, LLC.
This page lists
141
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2025 vs Q1 2025 Across Filers
Q1 2025 holders
142
Q2 2025 holders
140
Holder diff
-2
| Investor | Q1 2025 Shares | Q2 2025 Shares | Share Diff | Share Chg % | Q1 2025 Value $ | Q2 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.